$50M ATM Share Sale to RA Capital Extends Cash Runway to Key Phase 3 Data
IKT sits 54% above its 52-week low of $1.33.
Summary
Inhibikase Therapeutics sold 25 million shares to RA Capital Management through its ATM facility, raising $50 million in gross proceeds. The company expects this, along with existing cash, to fund operations through the topline data readout from Part B of the pivotal Phase 3 IMPROVE-PAH trial, contingent on full exercise of outstanding warrants. This follows a Q1 2026 net loss of $16.4 million and a cash position that provided only a 12-month runway. The sale represents significant dilution—roughly 20% of the pre-deal market cap—but secures a path to a major catalyst without an underwritten offering. The Phase 3 readout is now the critical event for the stock.
At the time of this announcement, IKT was trading at $2.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $258.8M. The 52-week trading range was $1.33 to $2.26. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.